3D InSight™ Liver Microtissues are standardized 3D liver models, produced using primary hepatocytes and non-parenchymal liver cells. These advanced, pharma-validated liver models accurately reflect the structure and biology of in vivo liver, delivering greater confidence in decision-making based on in vitro cell-based assays for liver injury and drug efficacy testing.
Explore key mechanisms of healthy and diseased liver function
Our liver microtissues are comprised of primary human or animal hepatocytes and non-parenchymal liver cell types, such as Kupffer cells and liver endothelial cells, resulting in native-tissue-like functionality. They exhibit albumin secretion, polarized cellular organization, robust cytochrome P450 activity, high mitochondrial function, and bile-acid transport to the bile canaliculi, and into the surrounding media. This long-lived model improves sensitivity for DILI prediction by enabling long-term drug exposure and by including a physiologically relevant ratio of primary hepatocytes to non-parenchymal cells.
Improve sensitivity for DILI prediction by employing long-term drug exposure
Tested with 110 compounds, 3D InSight™ Human Liver Microtissues showed 2x higher sensitivity than 2D PHH for detection of DILI compounds. Read the Arch Toxicol Paper
Ensure reproducibility and continuity in longitudinal and multi-site studies
Order standardized, pre-qualified liver models, certified for liver toxicology applications, such as DILI prediction, that are available for delivery direct to your lab when you’re ready to start experiments. Check our production schedule
Human and Animal-derived Liver Microtissues
Liver microtissues prepared from primary human hepatocytes (monoculture or co-culture with Kupffer cells and liver endothelial cells options available), produced biweekly.
Custom animal liver microtissues prepared from monkey, dog or rat primary hepatocytes (monoculture or co-culture with species-specific NPCs options available), produced on request.
“Making primary hepatocyte-derived liver microtissues containing the appropriate number of non-parenchymal cells is complicated. In a European consortium, which performed a ring trial with 3D liver models, multiple labs failed to produce liver models themselves despite all using the same protocol and donor cells. When using InSphero’s assay-ready 3D InSight™ Microtissues, you avoid high upfront costs and frustrations, so you can focus on the most important part: generating reproducible data with a robust 3D model you can rely on.”
RADINA KOSTADINOVA, PHD
3D InSight™ Liver Microtissue Product Manager